Vaximm AG

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.

VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens.
VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab, as part of a scientific collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
VAXIMM also has a neoantigen program currently in preclinical development in collaboration with NEC; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches.
The Vaximm platform is very well suited for targeting viral antigens.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
VXM01 targeting VEGFR-2
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
photo
Chief Executive Officer
Vaximm AG